Faraz Ali, MBA

The chief executive officer of Tenaya Therapeutics discussed the growing interest in genomic medicines in cardiology.

The chief executive officer of Tenaya Therapeutics discussed the company’s decision to supplement the gene transfer programs in its pipeline with gene editing programs.

The chief executive officer of Tenaya Therapeutics discussed the company’s research on capsids, promoters, and manufacturing improvements.